APGE · Apogee Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $60.82M | - | $54.18M | $55.70M | $46.39M | - | $45.71M | $33.21M | $28.72M | - |
| SG&A | $21.95M | - | $17.10M | $17.46M | $16.71M | - | $12.97M | $10.92M | $9.46M | - |
| Total Operating Expenses | $82.77M | - | $71.28M | $73.17M | $63.10M | - | $58.69M | $44.12M | $38.18M | - |
| D&A | $408.0K | - | $400.0K | $400.0K | $207.0K | - | - | - | $29.0K | - |
| Operating Income | ($82.77M) | - | ($71.28M) | ($73.17M) | ($63.10M) | - | ($58.69M) | ($44.12M) | ($38.18M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $79.0K | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | ($74.11M) | - | ($65.02M) | ($66.10M) | ($55.34M) | - | ($49.02M) | ($33.82M) | ($32.09M) | - |
| EPS - Basic | ($1.06) | - | ($1.11) | ($1.13) | ($0.95) | - | ($0.86) | ($0.60) | ($0.64) | - |
| EPS - Diluted | ($1.06) | - | ($1.11) | ($1.13) | ($0.95) | - | ($0.86) | ($0.60) | ($0.64) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $451.80M | $131.55M | $107.91M | $124.19M | $106.92M | $141.79M | $188.27M | $125.07M | $485.46M | $118.32M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.24M | $1.22M | $376.0K | $5.68M | $2.44M | $1.07M | $2.22M | $5.53M | $4.30M | $2.14M |
| Current Assets | $1.07B | $741.36M | $540.10M | $516.12M | $521.53M | $529.71M | $534.48M | $681.85M | $820.61M | $398.41M |
| Total Assets | $1.29B | $937.13M | $626.16M | $657.77M | $714.16M | $753.95M | $776.29M | $800.66M | $823.66M | $401.40M |
| Current Liabilities | $32.95M | $27.91M | $34.05M | $31.55M | $32.96M | $28.56M | $32.61M | $24.62M | $21.55M | $20.56M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $37.86M | $33.25M | $39.82M | $38.37M | $40.80M | $37.16M | $41.88M | $27.02M | $22.18M | $21.49M |
| Stockholders' Equity | - | - | - | - | - | - | - | - | - | - |
| Retained Earnings | ($635.87M) | ($561.76M) | ($492.37M) | ($427.35M) | ($361.25M) | ($305.92M) | ($238.70M) | ($189.68M) | ($155.86M) | ($123.77M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($55.57M) | - | - | - | ($48.48M) | - | - | - | ($31.64M) | - |
| Investing Cash Flow | ($35.35M) | - | - | - | $12.98M | - | - | - | ($51.74M) | - |
| Financing Cash Flow | $411.17M | - | - | - | $622.0K | - | - | - | $450.52M | - |
| CapEx | - | - | - | - | $4.32M | - | - | - | $351.0K | - |
| Free Cash Flow | - | - | - | - | ($52.79M) | - | - | - | ($31.99M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.95 | - | - | - | 1.00 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.7% | - | -10.4% | -10.0% | -7.7% | - | -6.3% | -4.2% | -3.9% | - |
| Return on equity | - | - | - | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 32.59 | 26.57 | 15.86 | 16.36 | 15.82 | 18.55 | 16.39 | 27.70 | 38.08 | 19.38 |
| Quick ratio | 32.59 | 26.57 | 15.86 | 16.36 | 15.82 | 18.55 | 16.39 | 27.70 | 38.08 | 19.38 |
| Cash ratio | 13.71 | 4.71 | 3.17 | 3.94 | 3.24 | 4.96 | 5.77 | 5.08 | 22.53 | 5.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | - | - | - | - | - | - | - | - | - | - |
| Liabilities / Assets | 0.03 | 0.04 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.03 | 0.03 | 0.05 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -31.2% | - | -21.5% | -65.8% | -65.3% | - | -141.5% | -133.6% | - | - |
| Net income growth (YoY) | -33.9% | - | -32.6% | -95.5% | -72.4% | - | -149.4% | -1762.1% | - | - |
| EPS growth (YoY) | -11.6% | - | -29.1% | -88.3% | -48.4% | - | -68.6% | 84.1% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -65.0% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Apogee Therapeutics against the 5 most active filers in the same SIC group.